Table 2.
Results of repeated variables over the follow-up study period eyes with mCNV (n = 41).
| Variable | baseline | 1 Month | 6 Months | 12 Months | p value |
|---|---|---|---|---|---|
| BCVA (logMAR) | 0.48 ± 0.34 | 0.34 ± 0.29 | 0.26 ± 0.24a | 0.28 ± 0.25b | 0.003A |
| Ellipsoid zone disruption (n) | 37 (90.5%) | 20 (61.9%) c | 3 (4.8%)d | 6 (9.5%)d | < 0.001Q |
| Subretinal hyperreflective exudation (n) | 39 (95.1%) | 19 (46.1%) d | 3 (7.3%)d | 1 (2.4%)d | < 0.001Q |
| Intraretinal cysts (n) | 11 (26.8%) | 10 (24.4%) | 4 (9.8%)e | 2 (4.9%)f | 0.002Q |
| Subretinal fluid (n) | 17 (41.5%) | 3 (7.3%) g | 1 (2.4%)d | 2 (4.9%)d | < 0.001Q |
| CNV area (mm2) | 0.61 ± 0.58 | 0.54 ± 0.55 | 0.50 ± 0.47 | 0.49 ± 0.48 | 0.736A |
| Subretinal fibrosis (n) | 0 (0%) | 0 (0%) | 10 (24.4%)h | 19 (46.3%)d | < 0.001Q |
Significant values are in bold.
AANOVA test; QCochran’s Q test; a0.004 (Tukey HSD vs baseline); b0.009 (Tukey HSD vs baseline); c0.001(McNemar vs baseline); d< 0.001(McNemar vs baseline); e0.039 (McNemar vs baseline); f0.012 (McNemar vs baseline); g0.001 (McNemar vs baseline); h0.002 (McNemar vs baseline).
BCVA Best-Corrected Visual Acuity, CNV Choroidal neovascularization, logMAR logarithm of the minimal angle of resolution, mm millimeter.